WHO WE ARE
The company was founded by two researchers, Joana Simões Correia and Ricardo Neves and one manager, Luísa Marques. The project that led to the creation of the company (Nanoinspire) participated in COHiTEC 2014 program and is the result of the research developed in collaboration between the Centre for Neurosciences and Cellular Biology of Coimbra University, Crioestaminal SA, and Biocant. Founded in June 2015, the company has so far secured €1M funding, of which €900K from venture capital firms, and in excess of €600K from a Portugal 2020 R&D grant.
Exo-T received the Young Entrepreneur Award by ANJE in 2015, and the Everis Award in 2016. In the same year, the company obtained the SME Instrument Phase 1 support from the European Commission, and in 2017 the company was a finalist of the Alira Health - EWMA (European Wound Management Association) Award, recognizing Exo-T as one of the top 5 most Innovative Companies worldwide in wound care.
Joana Simões Correia
Board and Advisors
Exogenus Therapeutics é uma start-up de base tecnológica dedicada ao desenvolvimento de terapias inovadoras. Com uma equipa jovem e dinâmica localizada no parque biotecnológico de Cantanhede (Biocant Park), pretende recrutar um estagiário para estágio IEFP para apoiar a atividade administrativa e financeira fazendo a ponte entre a Direção e os serviços de Contabilidade, com[…]
We are glad to announce that Graça Raposo, one of the first scientists worldwide who recognized the biological role of Extracellular Vesicles (EVs) in human biology, has joined our Advisory Board. Commonly referred within experts as “the mother of exosomes”, Graça Raposo has been extensively recognized in the field, and received many distinctions such as the CNRS[…]
Exogenus is presenting a poster at ISEV 2018 Annual meeting taking place in Barcelona between 2-6 May. With over 1,000 attendees, ISEV2018 gathers experts and researchers on extracellular vesicle research, covering the latest progresses in exosomes, microvesicles. Exogenus is one of the few companies worldwide developing EV-based therapeutics. Silvia Rodrigues is presenting a poster on “Development[…]
Exogenus is developing promising therapeutics for the treatment of chronic and acute wounds, among which are diabetic foot ulcers, some of the most debilitating and hard-to-heal. The lead technology licensed and under development by Exogenus for the treatment of wounds, is owned by Crioestaminal and Biocant, and relates to the use of exosomes secreted by[…]
Silvia Rodrigues, PhD student at Exogenus Therapeutics, presented a poster with results on research and development work done on the automatization of cord blood processing for production of an exosome-based medicinal product and its relevance for the scaling up of clinical-grade manufacturing process. Held in Coimbra in February 2018, the 1st Meeting on Vesicular Biology of[…]
Exogenus was recognized at BioEurope 2017, one of the biggest biotech industry events! Listen to Joana Simões Correia on Exogenus Therapeutics: Event organizers, EBD Group and Johnson & Johnson Innovation, recognized how hard a task it was to choose the winner at this edition. https://labiotech.eu/startup-slam-bio-europe-2017-winner/
Exogenus was one of the 20 biotech startups selected to participate at Bio Europe 2017 Startup Slam taking place on November 7th in Berlin. Participants will have the chance to present in front of a jury of investors, dealmakers and biotech KOL’s. Check out Labiotech’s article on the event. Joana Correia said: “Bio Europe Startup Slam is[…]
Exogenus was distinguished as one of the most innovative Life Sciences & Medtech projects in Europe at Merck Venture Lounge, 2017! The Venture Lounge is an initiative of EASME through SME Instrument Phase 3 services. https://ec.europa.eu/easme/en/news/pitching-contest-merck-venture-lounge-and-sme-instrument-starts-today Joana Correia on this award: “For a startup it’s really important to have the recognition of relevant industry players, special on[…]
Exosome Companies – Tiny Exosomes, Enormous Potential “Recently, exosomes have been gaining momentum as a novel strategy for accessing the therapeutic effects of stem cells without the risks and difficulties of administering the cells to patients. Exosome companies are multiplying in number, with new market entrants popping up rapidly.” in BioInformant
Joana Correia, Executive Director and Chief Scientific Officer presented last week at Cord Blood World Europe. Under the theme: “Umbilical cord blood supply for the development of Exo-Wound, an exosome-based product for chronic wounds” Joana talked about the technology behind Exo-Wound and the advantages and challenges of using exosomes as a therapeutic tool but also about[…]